Compare Brookfield Infrastructure Partners LP (BIP) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs GSK plc — how do they compare? Brookfield Infrastructure Partners LP trades at $39.54 (market cap $18.10B), while GSK plc trades at $50.37 (market cap $102.60B). The key difference: GSK plc is far larger — about 5.7× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.62%). Which is the better fit depends on your goals.
| BIP | GSK | |
|---|---|---|
Market Cap | $18.10B | $102.60B |
Sector | Industrials | Health |
52-Week High | $42.62 | $61.18 |
52-Week Low | $29.81 | $38.22 |
Enterprise Value | $77.05B | $123.04B |
Dividend Yield | 4.62% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.45, up 3.87% today, with a bullish technical signal from moving averages. The company reported revenue of $23.10B in 2025 but has missed recent EPS estimates, with Q2 2026 actual EPS at -$0.07 versus a $0.16 expectation. Recent news highlights its dividend appeal and corporate simplification plans, while analyst consensus remains strongly positive with a $44.67 price target.
BIP offers a high dividend yield and attractive EV/EBITDA valuation, but faces risks from earnings misses and high debt. The stock's upside depends on execution of its infrastructure strategy and improved profitability. Investor sentiment is buoyed by institutional support and media coverage emphasizing long-term value, though near-term volatility may persist amid macroeconomic uncertainty.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
